9th May, 2018: The University of Rwanda signed a collaboration agreement with L.E.A.F Rwanda. The aim of this agreement is to ensure upgrade, management and maintenance of biotechnology laboratory and knowledge transfer in research. The MoU was signed by UR Vice Chancellor and the Executive Chairman L.E.A.F Rwanda; a subsidiary of L.E.A.F Pharmaceuticals and was witnessed by staff from both parties
The signing of MoU by Prof. Cotton and Dr Niyikiza while DVCs for Finance & Strategic Planning look
Speaking during the signing of the Agreement, the UR Vice Chancellor Prof. Philip Cotton expressed his satisfaction for the collaboration with L.E.A.F Rwanda. He thanked Dr. Clet Niyikiza, the Founder & CEO of L.E.A.F Pharmaceuticals for contributing to biotechnology research development in University of Rwanda, the country and in the region.
“This agreement is very monumental to all the Universities of East Africa,” says Vice Chancellor.
In his remarks Dr. Clet Niyikiza shared his reasons for opening the branch of the company in Rwanda. He noted that he wants to close the gaps related to disparities in distribution of pharmaceutical products in Africa by making Africa and more closely Rwanda to prosper in biotechnology.
Prof Cotton (R) shakes hands with Dr Niyikiza after the signing of MoU
“Pharmaceutical products bypass Africa including Rwanda,” says Dr. Clet Niyikiza.
L.E.A.F Rwanda in partnership with Rwanda, is focusing on making Rwanda a hub for Biotechnology research and development. It is looking forward to making Rwanda the center for pharmaceutical manufacturing in Africa. L.E.AF Rwanda agreed to collaborate with UR as the national university in developing Rwandan expertise and capacity in biomedical research and development using the existing biotechnology laboratory. The company also pledged to upgrade UR’s biotechnology laboratory to meet international standards.
Participants pose for a group photo after the function
Story by Aluel Malaak (Intern in Communication Department)